Novartis Makes Site Decisions

1 September 1996

The newly-merged Swiss group Novartis is to make its headquarters in Basle. The Basle-St John site of Sandoz AG will be used for pharmaceuticals, while Ciba-Geigy's Rosental site will be the base for agrochemicals. The Swiss capital Berne will be the base for Novartis' nutritional and foods businesses.

Alex Krauer, president of Novartis, and Daniel Vassella, executive chairman, will maintain offices in both of the former headquarters of Ciba and Sandoz, the Novartis merger partners.

Ciba Vision will stay at Mechelen in the Benelux region, while Laeken will remain the main site for self-medication products. Administration and specialty chemicals in Italy will be located in Origgio near Milan.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight